Loading news...
BI Asset Management Fondsmaeglerselskab A S increased its position in shares of Insulet Corporation (NASDAQ: PODD) by 258.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,856 shares of the medical instruments supplier's stock after buying an additional
ACTON, Mass.--(BUSINESS WIRE)--Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care.
Pre-Market Stock Futures: Futures are trading mixed after a solid start to the week, with all the major indices, except the Russell 2000, finishing the day higher. Anticipation of earnings reports from mega-cap technology stocks, including Microsoft, Meta, and Tesla, and the January Federal Reserve meeting, where the Fed is expected to hold rates steady,... Here Are Tuesday's Top Wall Street Analyst Research Calls: Affirm Holdings, Alcoa, Block, Coinbase Global,CoreWeave, Datadog, Intuitive Surgical, and More.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Inscription Capital LLC purchased a new position in shares of Insulet Corporation (NASDAQ: PODD) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,259 shares of the medical instruments supplier's stock, valued at approximately $1,006,000. A number of other large investors
Explore the exciting world of Insulet (PODD 1.20%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
PODD is Intuitive Surgical's counterpart in the Health Care Equipment sector that has:
Insulet Corporation (PODD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on.
Asset Management One Co. Ltd. raised its position in Insulet Corporation (NASDAQ: PODD) by 29.0% during the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 38,401 shares of the medical instruments supplier's stock after acquiring an additional 8,622 shares during the period. Asset Management One Co.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its debut at Consumer Electronics Show (CES) 2026, where the Company will showcase its vision for liveable technology through an immersive booth experience, expert panel session, and media demonstrations. Liveable technology reflects Insulet's philosophy for the future of connected health: effortles.
Stagezero Life Sciences (OTCMKTS:SZLSF - Get Free Report) and Insulet (NASDAQ: PODD - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership. Earnings and Valuation This table compares Stagezero Life
PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.
Braun Stacey Associates Inc. acquired a new position in shares of Insulet Corporation (NASDAQ: PODD) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 53,952 shares of the medical instruments supplier's stock, valued at approximately $16,657,000. Braun Stacey Associates Inc.
GLDD, CIEN and PODD made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 31, 2025.
Osaic Holdings Inc. boosted its position in Insulet Corporation (NASDAQ: PODD) by 152.9% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,781 shares of the medical instruments supplier's stock after acquiring an additional 5,309 shares during the period. Osaic
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Central Pacific Bank Trust Division lowered its stake in shares of Insulet Corporation (NASDAQ: PODD) by 99.8% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 480 shares of the medical instruments supplier's stock after selling 291,000 shares during the quarter. Central Pacific